The Cost-Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine in Seven Chinese Cities

Ngā tūemi rite

• Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18–49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors
  mā: Laura L. Hammitt, me ētahi atu.
  I whakaputaina: (2023-01-01)
• Serotype Replacement after Introduction of 10-Valent and 13-Valent Pneumococcal Conjugate Vaccines in 10 Countries, Europe
  mā: Germaine Hanquet, me ētahi atu.
  I whakaputaina: (2022-01-01)
• A narrative review on vaccination rate and factors associated with the willingness to receive pneumococcal vaccine in Chinese adult population
  mā: Bai Yunhua, me ētahi atu.
  I whakaputaina: (2022-11-01)
• Immunogenicity of a 20-Valent Pneumococcal Conjugate Vaccine Versus a 13-Valent Vaccine in Infants: A Systematic Review and Meta-Analysis
  mā: María-Dolores Pacheco-Haro, me ētahi atu.
  I whakaputaina: (2025-11-01)
• Randomized Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of V114, a 15-Valent PCV, Followed by PPSV23 6 Months Later (PNEU-DAY): Subgroup Analysis in Adults 18–49 Years of Age Enrolled at Center for Indigenous Health Sites
  mā: Laura L. Hammitt, me ētahi atu.
  I whakaputaina: (2025-12-01)